Multiple sclerosis, idiopathic dilated cardiomyopathy, and insulin-dependent diabetes mellitus: A common mechanism of irregular immune regulation

Neurologist

Volumn 17, Issue 3, 2011, Pages 172-175

  Deretzi, Georgia ^a   Kountouras, Jannis ^b   Zavos, Christos ^b   Giartza Taxidou, Evangelia ^b   Koutlas, Evangelos ^a   Kiriazopoulou, Eleonora ^a   Tsiptsios, Iakovos ^a  

^a Neurology Department   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

autoimmunity; diabetes mellitus; idiopathic dilated cardiomyopathy; multiple sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; CARVEDILOL; FUROSEMIDE; METHYLPREDNISOLONE; MYELIN; SPIRONOLACTONE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; HEART MUSCLE CELL; HUMAN; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTIPLE SCLEROSIS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADULT; AUTOANTIBODIES; CARDIOMYOPATHY, DILATED; COMORBIDITY; DIABETES MELLITUS, TYPE 1; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 79955641659     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3182173552     Document Type: Article

References (47)

1. Compston A, Noseworth J, Lassmann H, et al. McAlpine's Multiple Sclerosis. 4th ed. London, UK: Elsevier; 2006.
2. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210-218. (Pubitemid 46466140)
3. Briggs FB, Goldstein BA, McCauley JL, et al; for the International Multiple Sclerosis Genetics Consortium. Variation within DNA repair pathway genes and risk of multiple sclerosis. Am J Epidemiol. 2010;172:217-224.
4. Somers EC, Thomas SL, Smeeth L, et al. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology. 2006;17:202-217.
5. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004;10:575-581. (Pubitemid 39207233)
6. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 2006;5:924-931. (Pubitemid 44556542)
7. Deretzi G, Kountouras J, Koutlas E, et al. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult Scler. 2010;16:1091-1101.
8. Nielsen NM, Westergaard T, Frisch M, et al. Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch Neurol. 2006;63:1001-1004. (Pubitemid 44036303)
9. Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology. 1999;53:883-885. (Pubitemid 29448322)
10. Marrosu MG, Cocco E, Lai M, et al. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet. 2002;359:1461-1465. (Pubitemid 34457762)
11. Hietaharju A, Peltola J, Seppa J, et al. The coexistence of systemic lupus erythematosus and multiple sclerosis in a mother and daughter. Scand J Rheumatol. 2001;30:120-122. (Pubitemid 32250804)
12. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827-836. (Pubitemid 41242675)
13. Attout H, Toussirot E, Auge B, et al. Rheumatoid arthritis and multiple sclerosis in the same patient: two case reports. Rev Rhum Engl Ed. 1999;66:169-172. (Pubitemid 29156812)
14. Tan FU, Tellioglu S, Aydin G, et al. Ankylosing spondylitis and multiple sclerosis in an HLA-B27 negative patient. Acta Neurol Belg. 2004;104:169-172. (Pubitemid 40277930)
15. Meiner Z, Zlotogorski A, Brautbar C. Pemphigus associated with multiple sclerosis. Clin Exp Dermatol. 1992;17:217.
16. Pelidou SH, Tsifetaki N, Giannopoulos S, et al. Multiple sclerosis associated with systemic sclerosis. Rheumatol Int. 2007;27:771-773. (Pubitemid 46716717)
17. Sellbach AN, Pender MP. Multiple sclerosis with idiopathic dilated cardiomyopathy: a case report. Eur Neurol. 2005;53:214-215. (Pubitemid 41404751)
18. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;8:1564-1575. (Pubitemid 24366905)
19. Kuethe F, Braun RK, Foerster M, et al. Immunopathogenesis of dilated cardiomyopathy. Evidence for the role of TH2-type CD4+T lymphocytes and association with myocardial HLA-DR expression. Clin Immunol. 2006;26:33-39. (Pubitemid 43112624)
20. Tsirogianni A, Pipi E, Soufleros K. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun Rev. 2009;8: 687-691.
21. Tisch R, Wang B. Dysrulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol. 2008;100:125-149.
22. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial background and rationale. Diabetes Metab Res Rev. 2009;25:321-324.
23. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58:840-846. (Pubitemid 41746873)
24. Alarcón-Riquelme ME. The genetics of shared autoimmunity. Autoimmunity. 2005;38:205-208. (Pubitemid 40959893)
25. Gregersen PK, Behrens TW. Genetics of autoimmune diseases-disorders of immune homeostasis. Nat Rev Genet. 2006;7:917-928. (Pubitemid 44871395)
26. Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;25:4.
27. Vandenbark AA, Offner H. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? Immunology. 2008;125:1-13.
28. Tian B, Hao J, Zhang Y, et al. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation. 2009;87:198-206.
29. Saresella M, Marventano I, Longhi R, et al. CD4+CD25+ FoxP3+PD1-regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008;22:3500-3508.
30. Peng SL. Transcription factors in autoimmune diseases. Front Biosci. 2008;13:4218-4240. (Pubitemid 351599681)
31. Spolski R, Leonard WJ. Cytokine mediators of Th17 function. Eur J Immunol. 2009;3:658-661.
32. Ponomarev ED, Dittel BN. Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J Immunol. 2005;174: 4678-4687.
33. Lassmann H. Experimental models of multiple sclerosis. Rev Neurol. 2007;163:651-655. (Pubitemid 47015564)
34. Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann N Y Acad Sci. 2001;928:200-211.
35. Huber SA. Autoimmunity in myocarditis: relevance of animal models. Clin Immunol Immunopathol. 1997;83:93-102. (Pubitemid 27195929)
36. Janewit D, Altuntas CZ, Monti J, et al. Sex-defined T-cell responses to cardiac self determine differential outcomes of murine dilated cardiomyopathy. Am J Pathol. 2008;172:11-21. (Pubitemid 351186363)
37. Limas CJ, Panayiotis I, Anyfantakis A et al. Familial clustering with dilated cardiomyopathy. Am J Cardiol. 2004;93:1189-1191.
38. Ramagopolan SV, Dyment DA, Valdar W et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 2007;6:604-610. (Pubitemid 46921044)
39. Somers EC, Thomas SL, Smeeth L, et al. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169:749-755.
40. Fernandez M, Giuliani A, Pirondi S, et al. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci U S A. 2004;101: 16363-16368. (Pubitemid 39552850)
41. Coughlin SS, Pearle DL, Baughman K, et al. Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol. 1994;4:67-74.
42. Kreisler A, de Seze J, Stojkovic T, et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand. 2003;107:154-157. (Pubitemid 36286807)
43. Polman CH, Kappos L, Dahlke F, et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology. 2005;64: 996-1000. (Pubitemid 40388450)
44. Sonneblink M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991;99:557-561.
45. Koshiyama H, Selliti DF, Akamizu T, et al. Cardiomyopathy associated with Graves' diseases. Clin Endocrinol. 1996;45: 111-116.
46. Boccalardo C, Boccalardo F, Orlander P, et al. Severe reversible dilated cardiomyopathy and hypothyroidism: case report and review of the literature. Endocr Pract. 2003;9:140-146.
47. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs. 2005;19:239-252. (Pubitemid 40460663)